GET DAILY SIGNALSALX Oncology Holdings (ALXO): What Investors Should Watch in the Q3 2026 Earnings Report
Key Takeaways
- ALX Oncology Holdings (ALXO), a clinical-stage immuno-oncology company, is expected to report its third quarter 2026 results for the period ended September 30, 2026, in November 2026, though an exact date had not been confirmed at the time of writing.
- Wall Street consensus points to a net loss of roughly $0.14 to $0.15 per share for the quarter, a sharp improvement from the $0.41 per-share loss reported in the same period a year earlier.
- As a development-stage biotech with no approved products, ALX Oncology reports no product revenue; investors will instead focus on operating expenses, cash burn, and clinical pipeline updates.
- The company's most recent quarter (Q2 2026) delivered a $0.13 per-share loss, beating consensus, continuing a trend of narrowing losses driven by cost discipline.
- Key catalysts to watch include updates on evorpacept, the lead CD47-blocking candidate, and ALX2004, an EGFR-targeted antibody-drug conjugate (ADC).
- Following a February 2026 registered offering of roughly $150 million, management has guided that its cash runway extends through the first half of 2028.
Earnings Context and Its Importance
ALX Oncology's quarterly results provide insight into how effectively the clinical-stage company manages its capital while moving its pipeline forward. With no marketed products, top-line revenue stays at zero, so attention turns to expenses, cash position, and clinical milestones instead of sales figures. The third quarter follows a $150 million capital raise that extended the cash runway into the first half of 2028 and comes after positive data supporting CD47 as a predictive biomarker for the lead candidate, evorpacept. For a small-cap biotech trading near multi-year lows, this report acts as both a financial checkup and a gauge of execution ahead of multiple data readouts expected over the next 12 to 18 months. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Expected Numbers for the Quarter
Analysts expect ALX Oncology to report a net loss of approximately $0.14 to $0.15 per share for the third quarter of 2026, based on consensus estimates from sources such as Zacks and MarketBeat. This compares with a $0.41 per-share loss in the third quarter of 2025, showing a notable year-over-year reduction in losses after workforce reductions, lower research and development spending, and pipeline prioritization. Revenue is projected at zero, in line with the company’s stage as a clinical developer without approved products. In the previous quarter (Q2 2026), the company reported a $0.13 per-share loss that beat the consensus estimate of a $0.14 loss, and it has beaten EPS estimates in several recent quarters. Beyond the headline loss, investors will monitor operating expenses, cash and investments, and any comments on enrollment and timelines for the ASPEN-09 breast cancer trial and the Phase 1 study of ALX2004. From what I see, these details often matter more than the EPS number itself for development-stage names.
Market Reaction and Current Sentiment
Sentiment ahead of the report appears cautious yet stabilizing. Shares hit a multi-year low near $0.86 in mid-October 2026 before recovering roughly 13% over the following 30 days, according to market data, as investors balanced the extended cash runway against ongoing clinical and execution risks. The consensus analyst rating stands at Moderate Buy, with an average price target near $4.60, well above recent trading levels and highlighting a gap between current valuation and longer-term expectations. Key risks include continued cash burn, the early-stage pipeline, and binary clinical outcomes. Because ALX Oncology lacks recurring revenue, any market reaction will likely depend more on shifts in guidance, trial timelines, or spending outlook than on the per-share loss alone. I’m watching this closely as the stock remains sensitive to pipeline news.
Looking Ahead at Key Factors
Beyond the third quarter, several clinical catalysts and financial signals deserve attention. The ASPEN-09 breast cancer trial evaluating evorpacept continues to enroll patients, with topline data expected around mid-2027. Updates on enrollment pace and any biomarker-driven adjustments will draw focus given the precision-oncology approach tied to CD47 expression. The Phase 1 trial of ALX2004, an EGFR-targeted antibody-drug conjugate, is advancing through dose escalation, with safety data from that phase anticipated in the second half of 2026. Any signals on dose-limiting toxicities or cohort progression could influence the asset’s path. On the financial side, the question remains whether the company can maintain its reduced expense base while advancing both programs. Management has indicated that existing cash, investments, and the term loan facility should support operations through the first half of 2028, though quarterly cash burn will be tracked to confirm that outlook. Nasdaq listing compliance also remains a consideration given the low share price. In clinical-stage biotechs, trial results rather than near-term earnings ultimately shape the investment story.
Using AI Tools for Biotech Research
In my analysis of names like ALX Oncology, I find it helpful to cross-reference peer data and technical signals with automated tools. One approach that has proven useful is applying AI-driven filters to quickly identify comparable companies and spot shifts in sector momentum without manual effort. This keeps the focus on the fundamentals and pipeline while adding context from broader market patterns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALXO's RSI Indicator ascending out of oversold territory
The RSI Indicator for ALXO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 25 of 40 cases over the following month. The odds of a continued upward trend are 62%.
Following a +10.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 212 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 46 cases where ALXO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALXO as a result. In 75 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The 50-day moving average for ALXO moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ALXO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.482). P/E Ratio (-1.004) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage company, which engages in the research and development of therapies for cancer patients
Industry Biotechnology
Advertisement